Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
<h4>Purpose</h4>Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children.<h4>Method</h4>From baseline, axial length growth over six months was measured prospectively. Subjects were then initia...
Guardado en:
Autores principales: | Loreto V T Rose, Angela M Schulz, Stuart L Graham |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/44d663cff92047a89290a806dcb7a59a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A multicenter Spanish study of atropine 0.01% in childhood myopia progression
por: Inés Pérez-Flores, et al.
Publicado: (2021) -
Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
por: Can Cui, et al.
Publicado: (2021) -
Risk factors for rapid axial length elongation with low concentration atropine for myopia control
por: Aicun Fu, et al.
Publicado: (2021) -
Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial
por: Ying Yuan, et al.
Publicado: (2021) -
Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
por: Po-Hsiang Kao, et al.
Publicado: (2021)